Food & Drug Commissioner Scott Gottlieb, M.D., wants to hear from consumers and the medical community regarding the warning messages that accompany drugs that are marketed directly to consumers. “In addition to providing consumers with the benefits of the potential treatment, today’s direct-to-consumer prescription drug advertisements must also present the risks. But if the risks aren’t provided in a way that consumers understand, they may not be able to appropriately weigh the benefits and risks”.
The FDA is seeking public comment until November 20, 2017. Individuals wishing to have their comments considered by the FDA can find information on how to submit those comments, either electronically or via standard mail, in the Federal Register.
See the attached document below for more information on the FDA’s request for public input into this issue.